{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-039220","form_type":"8-K","ticker":"PCSA","cik":"0001533743","company_name":"Processa Pharmaceuticals, Inc.","filed_at":"2024-10-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.717972+00:00","generated_at":"2026-05-30T22:27:04.774569+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Processa Pharmaceuticals doses first patient in Phase 2 trial of NGC-Cap for metastatic breast cancer","bullets":["First patient dosed in Phase 2 trial (NCT06568692) of NGC-Cap vs capecitabine in 60-90 advanced/metastatic breast cancer patients.","Phase 2 trial satisfies diligence milestone under license agreement with Elion Oncology for PCS6422; Condition Precedent date corrected to Oct 6, 2024.","Three clinical sites with IRB approval activated; plans for ~30 sites worldwide.","Interim analysis results from Phase 2 trial expected mid-2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-039220","json":"https://secwatch.observer/filing/0001493152-24-039220.json","markdown":"https://secwatch.observer/filing/0001493152-24-039220.md","text":"https://secwatch.observer/filing/0001493152-24-039220.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1533743/000149315224039220/0001493152-24-039220-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1533743/000149315224039220/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T22:27:04.774569+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}